JP2022542884A5 - - Google Patents
Info
- Publication number
- JP2022542884A5 JP2022542884A5 JP2022504569A JP2022504569A JP2022542884A5 JP 2022542884 A5 JP2022542884 A5 JP 2022542884A5 JP 2022504569 A JP2022504569 A JP 2022504569A JP 2022504569 A JP2022504569 A JP 2022504569A JP 2022542884 A5 JP2022542884 A5 JP 2022542884A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025051382A JP2025098167A (ja) | 2019-07-25 | 2025-03-26 | Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962878541P | 2019-07-25 | 2019-07-25 | |
| US62/878,541 | 2019-07-25 | ||
| PCT/US2020/043533 WO2021016571A2 (en) | 2019-07-25 | 2020-07-24 | Methods of treating antibody-mediated disorders with fcrn antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025051382A Division JP2025098167A (ja) | 2019-07-25 | 2025-03-26 | Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542884A JP2022542884A (ja) | 2022-10-07 |
| JP2022542884A5 true JP2022542884A5 (https=) | 2023-07-31 |
| JPWO2021016571A5 JPWO2021016571A5 (https=) | 2023-07-31 |
Family
ID=72087159
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504569A Pending JP2022542884A (ja) | 2019-07-25 | 2020-07-24 | Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法 |
| JP2025051382A Pending JP2025098167A (ja) | 2019-07-25 | 2025-03-26 | Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025051382A Pending JP2025098167A (ja) | 2019-07-25 | 2025-03-26 | Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210024620A1 (https=) |
| EP (1) | EP4004039A2 (https=) |
| JP (2) | JP2022542884A (https=) |
| KR (1) | KR20220038432A (https=) |
| CN (1) | CN114466663B (https=) |
| AU (1) | AU2020315925A1 (https=) |
| BR (1) | BR112022001255A2 (https=) |
| CA (1) | CA3148764A1 (https=) |
| CO (1) | CO2022001164A2 (https=) |
| IL (1) | IL290101A (https=) |
| MX (1) | MX2022001038A (https=) |
| TW (1) | TW202120539A (https=) |
| WO (1) | WO2021016571A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA71603A (fr) | 2022-07-27 | 2025-05-30 | Ablynx Nv | Polypeptides se liant à un épitope spécifique du récepteur fc néonatal |
| WO2024160721A1 (en) | 2023-01-30 | 2024-08-08 | Kymab Limited | Antibodies |
| JP2026506075A (ja) | 2023-02-17 | 2026-02-20 | アブリンクス エン．ヴェー． | 新生児型ｆｃ受容体に結合するポリペプチド |
| AR133188A1 (es) | 2023-07-05 | 2025-09-03 | Ablynx Nv | ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG |
| AU2024329349A1 (en) | 2023-08-23 | 2026-04-09 | Sanofi | Ctla-4-based lysosomal degraders and uses thereof |
| US20250154262A1 (en) | 2023-10-25 | 2025-05-15 | Ablynx N.V. | Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING |
| AR134267A1 (es) | 2023-11-08 | 2025-12-17 | Sanofi Sa | Degradador lisosómico basado en cd25 y usos del mismo |
| WO2025144848A1 (en) * | 2023-12-27 | 2025-07-03 | Vetmab Biosciences, Inc. | FcRn ANTAGONISTS FOR VETERINARY USE |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
| DK1817340T3 (da) * | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006130834A2 (en) * | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| WO2012132067A1 (ja) * | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
| TWI588156B (zh) | 2011-03-28 | 2017-06-21 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| TW201817744A (zh) * | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| JP6322411B2 (ja) * | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| KR20210094669A (ko) * | 2013-04-29 | 2021-07-29 | 에프. 호프만-라 로슈 아게 | 인간 fcrn-결합 변형된 항체 및 사용 방법 |
| US20170211876A1 (en) * | 2014-06-12 | 2017-07-27 | Hoffmann-La Roche Inc. | Method for selecting antibodies with modified fcrn interaction |
| RS59340B1 (sr) * | 2014-11-06 | 2019-10-31 | Hoffmann La Roche | Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe |
| MY188761A (en) * | 2015-03-09 | 2021-12-29 | Argenx Bvba | Method of reducing serum levels of fc-containing agents using fcrn antagonists |
| GB201618424D0 (en) * | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
| EP3625251A1 (en) * | 2017-05-15 | 2020-03-25 | University Of Rochester | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof |
| US12240875B2 (en) * | 2017-12-08 | 2025-03-04 | argenx BV | Use of FCRN antagonists for treatment of generalized myasthenia gravis |
| JP7399880B2 (ja) * | 2018-01-26 | 2023-12-18 | ジェンザイム・コーポレーション | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
-
2020
- 2020-07-24 EP EP20757029.2A patent/EP4004039A2/en active Pending
- 2020-07-24 TW TW109125184A patent/TW202120539A/zh unknown
- 2020-07-24 KR KR1020227005875A patent/KR20220038432A/ko active Pending
- 2020-07-24 US US16/938,727 patent/US20210024620A1/en active Pending
- 2020-07-24 AU AU2020315925A patent/AU2020315925A1/en active Pending
- 2020-07-24 MX MX2022001038A patent/MX2022001038A/es unknown
- 2020-07-24 JP JP2022504569A patent/JP2022542884A/ja active Pending
- 2020-07-24 WO PCT/US2020/043533 patent/WO2021016571A2/en not_active Ceased
- 2020-07-24 BR BR112022001255A patent/BR112022001255A2/pt unknown
- 2020-07-24 CN CN202080067562.1A patent/CN114466663B/zh active Active
- 2020-07-24 CA CA3148764A patent/CA3148764A1/en active Pending
-
2022
- 2022-01-24 IL IL290101A patent/IL290101A/en unknown
- 2022-02-04 CO CONC2022/0001164A patent/CO2022001164A2/es unknown
-
2025
- 2025-03-26 JP JP2025051382A patent/JP2025098167A/ja active Pending